Roche Experimental Leukemia Drug Helps Shrink Tumors

Roche Holding AG’s experimental leukemia drug shrank tumors in more patients when added to chemotherapy, according to study results that may aid the company in expanding its line of blood-cancer treatments.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.